Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million shares that the company had suggested on Monday . At $15 apiece, the biotech has also priced the shares, which will list on the Nasdaq today under the ticker “SCTX,” at the top end of the $13-15 range it had previously set out. It means the company expects to bring in $128.7 million in gross proce

Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solution that provides employers an

-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe -- -- Initial clinical data expected in 2027 -- July 23, 2026 -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.

Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for NEZGLYAL® (leriglitazone) as a treatment for male cALD patients, aged 2-12 years with Gadolinium (Gd) negative brai

Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA Zevra continues to support access to arimoclomol for eligible patients through its global Expanded Access Program July 24, 2026 -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Med

Enveda, a clinical-stage biotech company developing first-in-class small molecules derived from life’s chemistry, had results from its Phase 1b atopic dermatitis trial presented in New York at last week’s 2026 American Academy of Dermatology (AAD) Innovation Academy, and announced its acceptance for an oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna. “Patients want oral therapies; the problem is with our current orals, we take safety penal

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections1-3 By continuously delivering medicine into the eye through the Contivue® refillable implant, Susvimo may help people with nAMD maintain their vision with as few as two treatments per year1-3

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing author

Eli Lilly plans to file for FDA approval of retatrutide in the first quarter of 2027 after the so-called 'triple-G' drug, which targets the GIP, GLP-1 and glucagon receptors, delivered "substantial" weight loss in two further late-stage obesity studies. The company said Thursday that it is currently completing the Chemistry, Manufacturing, and Controls (CMC) data package required for the submission. "With the positive results from TRIUMPH-2 and TRIUMPH-3, we now have the clinical data package t

US$4.6 million financing fully capitalizes N-Zyme Biomedical’s planned Phase 2 clinical programs in laryngopharyngeal reflux and PPI-refractory GERD, supporting the advancement of its first-in-class pepsin-targeted therapeutic approach. N-Zyme Biomedical today announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for refl